Loading
Total declarations
Companies
▲ Purchases (533 ops.)
▼ Sales (91 ops.)
Latest filing published 14 Mar 2012 for Ocera Therapeutics, Inc., €23k.
Filing timeline
BuySaleBaker Brothers Life Sciences Capital (GP), LLC
First 200 filings with a declared amount
Insider track record
Disclosed buys
533
Disclosed sells
91
Signal history
No signal scores available.
Closed purchases
Market purchases
533
Positive at T+90
68%
Median T+90
+25.4%
Based on 82 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +7.8%Entry US$17.79 · Close at T+365 US$19.18
- +25.3%Entry US$13.20 · Close at T+365 US$16.54
- +33.5%Entry US$13.60 · Close at T+365 US$18.16
- +25.4%Entry US$13.96 · Close at T+365 US$17.50
- +484.9%Entry US$2.05 · Close at T+365 US$11.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Baker Brothers Life Sciences Capital (GP), LLC: trading record in brief
Baker Brothers Life Sciences Capital (GP), LLC has filed trades across 16 companies (mainly through SEC (Form 4)), most often in Genomic Health Inc, Incyte Corp and Seagen Inc. Between 25 April 2006 and 14 March 2012, the trades on record add up to 670 filings.
The open-market side counts 533 purchases for €483.3M alongside 91 sales for €81.5M. Netting one side against the other leaves €401.8M of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 9 share grants. So far in 2012, the count stands at 53 purchases and no sales.
Half of the purchases are above €361k and half below. After 82 purchases with a full 90-day history, the hit rate stands at 68% and the median 90-day move at +25.4%. This is a record of the past, not a forecast.
The newest entry dates from 14 March 2012: an open-market purchase of €79k, in Ocera Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Baker Brothers Life Sciences Capital (GP), LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations638 total
16,326 shares@ US$1.8858Common StockSEC:0001144204-12-014965:0
Canonical exit: 10 Jun 2012 (T+90)
44,467 shares@ US$1.87Common StockSEC:0001144204-12-014965:1
Canonical exit: 10 Jun 2012 (T+90)
327,769 shares@ US$2.3396Common StockSEC:0001144204-12-014965:2
Canonical exit: 10 Jun 2012 (T+90)
572,737 shares@ US$2.55Common StockSEC:0001144204-12-014965:3
Canonical exit: 10 Jun 2012 (T+90)
159,015 shares@ US$2.9581Common StockSEC:0001144204-12-014965:4
Canonical exit: 11 Jun 2012 (T+90)
56,294 shares@ US$2.9891Common StockSEC:0001144204-12-014965:5
Canonical exit: 12 Jun 2012 (T+90)
34,544 shares@ US$3.0055Common StockSEC:0001144204-12-014965:6
Canonical exit: 12 Jun 2012 (T+90)
22,071 shares@ US$29.8792Common StockSEC:0001144204-12-014099:0
Canonical exit: 5 Jun 2012 (T+90)
19,513 shares@ US$30.3638Common StockSEC:0001144204-12-014099:1
Canonical exit: 6 Jun 2012 (T+90)
15,288 shares@ US$29.4704Common StockSEC:0001144204-12-013006:0
Canonical exit: 30 May 2012 (T+90)
91,459 shares@ US$29.5205Common StockSEC:0001144204-12-013006:1
Canonical exit: 31 May 2012 (T+90)
85,231 shares@ US$29.9561Common StockSEC:0001144204-12-013006:2
Canonical exit: 3 Jun 2012 (T+90)
69,783 shares@ US$30.0688Common StockSEC:0001144204-12-013006:3
Canonical exit: 3 Jun 2012 (T+90)
36,881 shares@ US$29.0306Common StockSEC:0001144204-12-012152:0
Canonical exit: 27 May 2012 (T+90)
51,248 shares@ US$29.1085Common StockSEC:0001144204-12-012152:1
Canonical exit: 28 May 2012 (T+90)
156,902 shares@ US$29.0581Common StockSEC:0001144204-12-012152:2
Canonical exit: 29 May 2012 (T+90)
46,909 shares@ US$27.9769Common StockSEC:0001144204-12-010672:0
Canonical exit: 21 May 2012 (T+90)
5,511 shares@ US$27.9811Common StockSEC:0001144204-12-010672:1
Canonical exit: 22 May 2012 (T+90)
62,098 shares@ US$28.1238Common StockSEC:0001144204-12-010672:2
Canonical exit: 23 May 2012 (T+90)
55,804 shares@ US$28.437Common StockSEC:0001144204-12-009721:0
Canonical exit: 14 May 2012 (T+90)
32,125 shares@ US$28.8772Common StockSEC:0001144204-12-009721:1
Canonical exit: 15 May 2012 (T+90)
349 shares@ US$28.9625Common StockSEC:0001144204-12-009721:2
Canonical exit: 16 May 2012 (T+90)
93,088 shares@ US$29.6106Common StockSEC:0001144204-12-009721:3
Canonical exit: 16 May 2012 (T+90)
91,543 shares@ US$29.8548Common StockSEC:0001144204-12-009721:4
Canonical exit: 16 May 2012 (T+90)
6,093 shares@ US$26.1651Common StockSEC:0001144204-12-007402:0
Canonical exit: 8 May 2012 (T+90)
25 of 638 declarations
